Overview
The marketing authorisation for Imatinib Medac has been withdrawn at the request of the marketing authorisation holder.
Imatinib medac : EPAR - Summary for the public
Product information
Imatinib medac : EPAR - Product Information
Latest procedure affecting product information: IB/0009
11/04/2018
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Imatinib medac : EPAR - All Authorised presentations
Product details
- Name of medicine
- Imatinib medac
- Active substance
- imatinib
- International non-proprietary name (INN) or common name
- imatinib
- Therapeutic area (MeSH)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Dermatofibrosarcoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Myelodysplastic-Myeloproliferative Diseases
- Hypereosinophilic Syndrome
- Anatomical therapeutic chemical (ATC) code
- L01XE01
Pharmacotherapeutic group
Protein kinase inhibitorsTherapeutic indication
Imatinib medac is indicated for the treatment of:
- paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;
- paediatric patients with Ph+CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase;
- adult and paediatric patients with Ph+CML in blast crisis;
- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) integrated with chemotherapy;
- adult patients with relapsed or refractory Ph+ALL as monotherapy;
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;
- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement;
- adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
The effect of imatinib on the outcome of bone marrow transplantation has not been determined.
In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP.
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.
Assessment history
Imatinib medac : EPAR - Procedural steps taken and scientific information after authorisation